In the perimenopausal years, when E2 synthesis becomes variable and fluctuating, and FSH increases, the risk of the appearance of the metabolic syndrome increases significantly; when E2 decline is established with menopause, the metabolic syndrome is clearly higher than in premenopausal years (49). The gene discussed is BRD2; the disease is metabolic syndrome.